Abstract
A study was carried out to investigate the bioequivalence of the drugs "Doxitron chewable tablets" and "Ronaxan" when administered to dogs. Two groups of animals were formed with 4 dogs in each group. A cross-sectional study design was used for the experiment. Biological material (blood) was sampled before drug administration, and 15, 30, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 8, 10, 24, 30, 48, 72 h after drug administration. In the course of the study the following parameters were controlled: concentrations of the active substance of the preparations in the blood plasma of dogs. The article describes in detail the scheme of the experiment, reagents and standard samples, the process of sample preparation of blood plasma samples and HPLC-MS/MS analysis. The bioequivalence of the preparations "Doxitron chewable tablets" and "Ronaxan" is evaluated. The time to reach the maximum plasma concentration (Tmax) averaged 3.0 h for the investigational drug "Doxitron chewable tablets" and 3.0 h for the reference drug "Ronaxan". The maximum plasma concentration (Cmax) was 4007.4±964.4 ng/ml for the study drug Doxitron Chewable Tablets and 3794.9±1121.5 ng/ml for the reference drug Ronaxan. The 90% confidence intervals of CmaxT/CmaxR and AUC0-tT/AUC0-tR ratios of doxycycline were within the range of 80-125%. The preparations "Doxitron chewable tablets" and "Ronaxan" are bioequivalent.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
